A Focus on New Therapies for ADHD: Expanding Treatment Options for Patients

Program Description

Attention-deficit/hyperactivity disorder (ADHD) is a common neurobehavioral condition that, while often diagnosed in childhood, persists into adulthood for about half of children and adolescents. In addition to positive behavioral modification interventions, medication options for children aged at least 6 years are available. Stimulant medications have been used as first-line pharmacologic treatment options. Although these medications are highly effective in reducing ADHD symptoms, they are associated with high abuse potential. Newer, nonstimulant treatments for ADHD with novel mechanisms of action and drug delivery systems are emerging. Clinical efficacy and safety data for both stimulant and nonstimulant ADHD therapies will be reviewed. Prior to treatment initiation and during the course of therapy, pharmacists and pharmacy technicians can be involved in providing disease and therapy education to patients and their caregivers, assessing medication adherence, and helping to manage adverse effect profiles of available agents. This program features counseling video vignettes highlighting approaches for pharmacists and pharmacy technicians to address potential adherence barriers and prepare caregivers and patients with ADHD to initiate treatment.

Target audience: Health-system pharmacists, pharmacy technicians, retail pharmacists, specialty pharmacists

Type of activity: Application for pharmacists; Knowledge for pharmacy technicians

Release date: January 24, 2023
Expiration date: March 24, 2023

Time to complete activity: 1 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

Pharmacist Educational Objectives

• Explore the clinical impact of attention-deficit/hyperactivity disorder (ADHD) in children or adolescents and adults, including treatment challenges and gaps in care
• Analyze the latest clinical data on new and emerging pharmacotherapies for ADHD
• Employ treatment recommendations and patient counseling strategies to improve patient outcomes in ADHD

Pharmacy Technician Educational Objectives

• Describe the signs and symptoms of attention-deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults
• Recall the rationale for use of new and emerging pharmacotherapies for ADHD
• Recognize opportunities for pharmacy technicians to support pharmacists with improving ADHD treatment adherence

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity numbers 0290-0000-22-558-L01-P and 0290-0000-22-562-L01-T. The activity is available for CE credit through March 24, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Austin Campbell, PharmD, BCPP, has the following financial relationships with commercial interests to disclose:
Grant/Research Support: Intra-Cellular Therapies

Speakers Bureau: Sunovion Pharmaceuticals, Inc.

Other support: UpToDate

The following contributors have no relevant financial relationships with commercial interests to disclose:

Medical Writer

Jill O’Donnell, PharmD, BCPS, BCGP

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Michelle C. Carlson, PharmD; Kylie Ferrentino; Lauren Assennata; Susan Pordon; Brianna Winters; and Chloe Taccetta.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms